Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KYNU | Q16719 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.57 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.57 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.57 |
| ▸ | CTSK | P43235 | 4/20 | 0.53 |
| ▸ | CTSS | P25774 | 3/20 | 0.52 |
| ▸ | CTSL | P07711 | 2/20 | 0.52 |
| ▸ | CTSB | P07858 | 1/20 | 0.52 |
| ▸ | CASP1 | P29466 | 2/20 | 0.52 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.51 |
| ▸ | TACR1 | P25103 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11053442 | 1.00 | KYNU (0.59) | KYNUALDH1A1ALOX15SIRT2SIRT1 | |
| SCHEMBL26739782 | 0.95 | ALDH1A1 (0.56) | KYNUALDH1A1ALOX15SIRT2SIRT1 | |
| SCHEMBL8224981 | 0.95 | KYNU (0.59) | KYNUALDH1A1ALOX15SIRT2SIRT1 | |
| SCHEMBL220498 | 0.92 | FOLH1 (0.56) | KYNUALDH1A1ALOX15SIRT2SIRT1 | |
| SCHEMBL5970693 | 0.92 | FOLH1 (0.56) | KYNUALDH1A1ALOX15SIRT2SIRT1 | |
| SCHEMBL6299667 | 0.92 | FOLH1 (0.56) | KYNUALDH1A1ALOX15SIRT2SIRT1 | |
| SCHEMBL20696435 | 0.91 | ALDH1A1 (0.59) | KYNUALDH1A1ALOX15CTSKCTSS | |
| SCHEMBL6259518 | 0.90 | KYNU (0.60) | KYNUALDH1A1ALOX15SIRT2SIRT1 | |
| SCHEMBL2777678 | 0.90 | KYNU (0.60) | KYNUALDH1A1ALOX15SIRT2SIRT1 | |
| SCHEMBL221391 | 0.90 | KYNU (0.60) | KYNUALDH1A1ALOX15SIRT2SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4622959-A1 | 2-AMINO-N-(4-AMINO-3,4-DIOXO-1-(2-OXOPYRROLIDIN-3-YL)BUTAN-2-YL)BENZAMIDE DERIVATIVES AS PROTEASE INHIBITORS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION | Merck Sharp & Dohme LLC (US) | 2025-10-01 | — | — | EP | disclosed |
| US-20250243187-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2025-07-31 | — | — | US | disclosed |
| EP-4551569-A1 | ANTI-VIRAL COMPOUNDS | Aligos Therapeutics, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| US-20240228535-A1 | PROTEASE INHIBITORS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION | MERCK SHARP & DOHME LLC (US) | 2024-07-11 | — | — | US | disclosed |
| CN-118159548-A | Antiviral compounds | 安力高医药股份有限公司 | 2024-06-07 | — | — | CN | disclosed |
| WO-2024112621-A1 | 2-AMINO-N-(4-AMINO-3,4-DIOXO-1-(2-OXOPYRROLIDIN-3-YL)BUTAN-2-YL)BENZAMIDE DERIVATIVES AS PROTEASE INHIBITORS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION | MERCK SHARP & DOHME LLC (US) | 2024-05-30 | — | — | WO | disclosed |
| EP-4366831-A1 | ANTI-VIRAL COMPOUNDS | Aligos Therapeutics, Inc. (US) | 2024-05-15 | — | — | EP | disclosed |
| US-20240109871-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-04-04 | — | — | US | disclosed |
| US-20240018126-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-01-18 | — | — | US | disclosed |
| US-20240018126-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-01-18 | — | — | US | disclosed |
| US-11851422-B2 | Anti-viral compounds | ALIGOS THERAPEUTICS, INC. | 2023-12-26 | — | — | US | disclosed |
| US-20230093249-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-03-23 | — | — | US | disclosed |
| WO-2023283256-A1 | ANTI-VIRAL COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2023-01-12 | — | — | WO | disclosed |
| EP-1184388-B1 | SULPHOSTIN ANALOGUES AND PROCESSES FOR THE PREPARATION OF SULPHOSTIN AND ANALOGUES THEREOF | ZAIDAN HOJIN BISEIBUTSU (JP) | 2003-07-30 | — | — | EP | disclosed |
| US-6579989-B1 | Dipeptidylpeptidase IV inhibitors; hormone and immune modu-laters; anti-HIV and antiallergenic agents | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 2003-06-17 | — | — | US | disclosed |
| EP-1184388-A1 | SULPHOSTIN ANALOGUES AND PROCESSES FOR THE PREPARATION OF SULPHOSTIN AND ANALOGUES THEREOF | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 2002-03-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228535-A1 | PROTEASE INHIBITORS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION | PRSS1, PRSS2, ACE2 | KYNU 288/4885ALDH1A1 4236/4885ALOX15 3427/4885 |
| US-20250243187-A1 | ANTI-VIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, HAVCR2 | KYNU 4409/4885ALDH1A1 2039/4885ALOX15 3208/4885 |
| US-20230093249-A1 | ANTI-VIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, HAVCR2 | KYNU 4409/4885ALDH1A1 2039/4885ALOX15 3208/4885 |
| US-11851422-B2 | Anti-viral compounds | EIF2AK2, ZC3HAV1, HAVCR2 | KYNU 4409/4885ALDH1A1 2039/4885ALOX15 3208/4885 |
| US-20240018126-A1 | ANTI-VIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, HAVCR2 | KYNU 4409/4885ALDH1A1 2039/4885ALOX15 3208/4885 |
| US-20240109871-A1 | ANTI-VIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, HAVCR2 | KYNU 4409/4885ALDH1A1 2039/4885ALOX15 3208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.